Assembly Biosciences (NASDAQ:ASMB) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Assembly Biosciences (NASDAQ:ASMB) in a report released on Monday morning,Benzinga reports. The firm currently has a $50.00 target price on the biopharmaceutical company’s stock.

ASMB has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Wednesday, October 8th. Citizens Jmp assumed coverage on Assembly Biosciences in a research report on Wednesday, September 24th. They issued an “outperform” rating and a $38.00 target price on the stock. JMP Securities started coverage on shares of Assembly Biosciences in a report on Wednesday, September 24th. They issued a “market outperform” rating and a $38.00 price target on the stock. Citigroup started coverage on shares of Assembly Biosciences in a research report on Wednesday, September 24th. They set an “outperform” rating for the company. Finally, Mizuho set a $40.00 price objective on shares of Assembly Biosciences and gave the company an “outperform” rating in a report on Thursday, November 20th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.00.

Assembly Biosciences Stock Up 2.6%

ASMB stock opened at $36.18 on Monday. The stock has a market capitalization of $572.37 million, a PE ratio of -7.55 and a beta of 1.14. Assembly Biosciences has a 52 week low of $7.75 and a 52 week high of $39.71. The firm has a 50 day moving average of $33.44 and a 200 day moving average of $25.61.

Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.22). Assembly Biosciences had a negative net margin of 103.65% and a negative return on equity of 59.01%. The company had revenue of $10.79 million for the quarter, compared to analyst estimates of $7.46 million. On average, equities research analysts expect that Assembly Biosciences will post -6.87 earnings per share for the current year.

Hedge Funds Weigh In On Assembly Biosciences

Several large investors have recently made changes to their positions in ASMB. Farallon Capital Management LLC acquired a new stake in Assembly Biosciences in the 3rd quarter valued at $31,426,000. RA Capital Management L.P. purchased a new position in Assembly Biosciences during the third quarter valued at $26,122,000. Commodore Capital LP acquired a new stake in shares of Assembly Biosciences in the third quarter valued at about $25,600,000. Vanguard Group Inc. increased its stake in shares of Assembly Biosciences by 97.8% during the third quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock worth $12,854,000 after purchasing an additional 248,287 shares in the last quarter. Finally, Parkman Healthcare Partners LLC purchased a new stake in shares of Assembly Biosciences during the third quarter worth about $6,425,000. 19.92% of the stock is currently owned by institutional investors and hedge funds.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.